![Len Rosenberg](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Len Rosenberg
Keine laufenden Positionen mehr
Karriereverlauf von Len Rosenberg
Ehemalige bekannte Positionen von Len Rosenberg
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Diasome Pharmaceuticals, Inc.
![]() Diasome Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diasome Pharmaceuticals, Inc. operates as a clinical stage diabetes therapeutics company which designs and develops insulin-based therapies for the treatment of diabetes. It focuses on the clinical and commercial development of breakthrough therapies for diabetes and obesity. The company’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. The firm’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells. The company was founded by Len Rosenberg, Lance Converse, W. Blair Geho and Robert Geho in 2004 and is headquartered in Cleveland, OH. | Direktor/Vorstandsmitglied | 01.01.2004 | - |
Vorstandsvorsitzender | 01.01.2004 | 09.01.2014 | |
Geschäftsführer | 01.01.2004 | 09.01.2014 | |
Gründer | 28.08.2009 | - | |
Präsident | 01.01.2004 | - |
Statistik
International
Vereinigte Staaten | 2 |
Operativ
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Chief Operating Officer | 1 |
Sektoral
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Diasome Pharmaceuticals, Inc.
![]() Diasome Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diasome Pharmaceuticals, Inc. operates as a clinical stage diabetes therapeutics company which designs and develops insulin-based therapies for the treatment of diabetes. It focuses on the clinical and commercial development of breakthrough therapies for diabetes and obesity. The company’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. The firm’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells. The company was founded by Len Rosenberg, Lance Converse, W. Blair Geho and Robert Geho in 2004 and is headquartered in Cleveland, OH. | Health Technology |
- Börse
- Insiders
- Len Rosenberg
- Erfahrung